Vol. 1, Issue 4 ‣ July 2024
|
|
|
AMR is an evolving global health threat
|
|
|
The World Health Organization (WHO) recently released its 2024 Bacterial Priority Pathogens List (BPPL). The 72-page document builds on its first list, released in 2017. The WHO BPPL 2024 focuses on the antibiotic-resistant bacteria that present the greatest unmet needs and pose the most significant public health burdens. The list includes 15 families of antibiotic resistant pathogens grouped as critical, high and medium categories. The WHO’s intent to prioritize the pathogens within the categories is aimed to inform research and development teams and public health organizations to push developers of antibacterial medicines, research institutions, research funders and policy-makers to develop more regionally tailored strategies to effectively combat antimicrobial resistance.
|
|
|
Carbapenem-resistant Acinetobacter baumannii, listed as Critical priority by the WHO
|
|
|
In a press release, Dr Jérôme Salomon, WHO's Assistant Director-General for Universal Health Coverage, Communicable and Noncommunicable Diseases, said “Antimicrobial resistance jeopardizes our ability to effectively treat high burden infections, such as tuberculosis, leading to severe illness and increased mortality rates."
|
|
|
NG-Test® CARBA 5 can be used for the detection of the "Big 5" carbapenemases
|
|
The authors of the 2020 BPPL claim the rationale to update the list is due to a substantial gap to properly address the unmet needs of patients because the research and development of antibacterial agents have not kept pace with the rapid evolution of resistance. The determination of the weighted criteria to categorize the pathogens are based on eight attributes, followed by a blinded global survey of 79 experts from all six WHO regions. The attributes are: mortality, incidence, non-fatal health burden, trend of resistance, transmissibility, preventability in healthcare setting and community, treatability, and pipeline.
|
|
|
Keep reading to discover the critical and high-priority antibiotic-resistant bacteria identified in the WHO's 2024 Bacterial Priority Pathogens List and their significant global health impact, particularly in low to middle-income countries.
|
|
|
Product Spotlight:
HARDYDISK™
|
|
|
|
|
Discover Hardy Diagnostics' comprehensive range of antibiotic sensitivity disks designed to support accurate and efficient antimicrobial susceptibility testing in your laboratory. Explore our selection of high-quality products, including both standard and specialty disks, that ensure reliable results and help combat the growing challenge of antimicrobial resistance.
|
|
|
Also available: NG-Test® CARBA 5 / HardyCHROM CRE
|
|
|
NG-Test® CARBA 5 is the only FDA-cleared, rapid, multiplex, phenotypic test capable of detecting KPC, VIM, IMP, NDM and OXA-48-like carbapenemases produced by Enterobacterales and
P. aeruginosa.
|
HardyCHROM™ CRE (Carbapenem Resistant Enterobacterales) is a selective and differential chromogenic agar medium intended for the qualitative and presumptive detection from stool specimens of Escherichia coli.
|
|
|
|
Find us at booth #5019 and mention you saw our newsletter.
Keep Calm and Streak On!
|
|
|
Can't make it? Come see us in August at AOAC in Baltimore
Aug. 23-28 • Booth #510
|
|
|
AMR is one of the top 10 global public health threats facing humanity. It affects people, animals, and the environment and is driven by the misuse of antimicrobials.
|
|
Infections like pneumonia, tuberculosis, blood poisoning, gonorrhea, and foodborne diseases are becoming harder to treat due to AMR.
|
|
|
By 2050, AMR could cause up to 10 million deaths annually and result in an economic loss of USD 100 trillion.
|
|
Combatting AMR requires a unified approach involving humans, animals, plants, and the environment.
|
|
|
Video/Catalog Spotlight:
Susceptibility Testing & AMR
|
See our collection of HardyDisk™ videos and catalogs
|
|
|
|
|
Megan Maloney Roesner, an award-winning journalist, marketer, and current Clinical Microbiology Laboratory Marketing Product Manager at Hardy Diagnostics, brings over 20 years of experience in brand management, healthcare marketing, and communications to her role:
"Welcome back to Clinical MICRObits! In this issue, we explore the escalating global health threat of antimicrobial resistance (AMR) with insights from the WHO's 2024 Bacterial Priority Pathogens List. Discover the critical and high-priority antibiotic-resistant bacteria that pose significant public health challenges, particularly in low to middle-income countries. Make sure to subscribe if you haven't done so already!"
If you have any suggestions for content, a comment, or a question, please contact Megan here.
|
|
|
"A Culture of Service"
Hardy Diagnostics, 1430 West McCoy Lane, Santa Maria, CA, 93455, USA, +1.800.266.2222
|
|
|
|
